Literature DB >> 1826700

Signaling via the inositol phospholipid pathway by T cell antigen receptor is limited by receptor number.

M Graber1, L K Bockenstedt, A Weiss.   

Abstract

Engagement of the TCR initiates at least two transmembrane signaling pathways, the phosphatidylinositol pathway and a tyrosine kinase pathway. The T cell leukemic line Jurkat was used to study the relationship between the number of occupied TCR on the cell surface and the TCR-mediated activation of phosphatidylinositol-specific phospholipase C. We characterized a series of Ti beta-chain transfectants of the Jurkat mutant J.RT3-T3.5, in which surface expression of the TCR is limited by expression of the TCR beta-chain. Calibrated flow cytometry was used to determine the number of binding sites for anti-CD3 mAb on the surface of these cells, which was less than 1.2 x 10(3) to 1.2 x 10(4) sites/cell. In the presence of lithium chloride, the accumulation of inositol phosphates (InsP) in these cell lines in response to saturating concentrations of anti-CD3 mAb was proportional to the calculated surface TCR number. This result was consistent with dose-response studies using anti-CD3 mAb in Jurkat cells, in which ligand concentration, rather than number of binding sites, was limiting. Increase in intracellular free calcium concentration was a sensitive indicator of TCR engagement and correlated with the level of TCR expression, but less closely than did InsP levels. Induction of the early lymphocyte activation marker CD69 by anti-CD3 mAb also correlated with surface expression of TCR. In order to test whether limitation of this signaling pathway by TCR number may be relevant to signal transduction in the wild-type cell, we compared PLC activity in Jurkat cells during soluble anti-CD3 mAb-induced internalization of the TCR and also in response to immobilized mAb. The net accumulation of InsP per min decreased linearly with TCR number during the rapid phase of TCR internalization, confirming the limiting role of TCR number in this system. When internalization was prevented by immobilization of the stimulus, there was no decrease in the net accumulation of InsP per minute over time. In a Jurkat cell line transfected with the heterologous human muscarinic receptor, subtype 1, the InsP response to a muscarinic agonist was unaffected by TCR internalization, indicating that the distal phosphatidylinositol pathway was not affected by prolonged stimulation of the TCR. We conclude that transmembrane signaling through the TCR may be regulated by the number of surface TCR-ligand complexes. This observation has implications for transmembrane signaling in both mature T cells and thymocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826700

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Bim is required for T-cell allogeneic responses and graft-versus-host disease in vivo.

Authors:  Yu Yu; Jing Yu; Cristina Iclozan; Kane Kaosaard; Claudio Anasetti; Xue-Zhong Yu
Journal:  Am J Blood Res       Date:  2012-01-01

2.  Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells.

Authors:  Z Cai; A Brunmark; M R Jackson; D Loh; P A Peterson; J Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

3.  The inositol 1,4,5-trisphosphate receptor is essential for T-cell receptor signaling.

Authors:  T Jayaraman; E Ondriasová; K Ondrias; D J Harnick; A R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

4.  A functional T-cell receptor signaling pathway is required for p95vav activity.

Authors:  J Wu; S Katzav; A Weiss
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

5.  Ca2+ signaling in T lymphocytes: the interplay of the endoplasmic reticulum, mitochondria, membrane potential, and CRAC channels on transcription factor activation.

Authors:  Pei-Chi Yang; M Saleet Jafri
Journal:  Heliyon       Date:  2020-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.